Fig. 4: Protective efficacy of bivalent and trivalent VLP-S mixtures in Syrian hamsters. | Nature Communications

Fig. 4: Protective efficacy of bivalent and trivalent VLP-S mixtures in Syrian hamsters.

From: Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine

Fig. 4: Protective efficacy of bivalent and trivalent VLP-S mixtures in Syrian hamsters.

● or † indicate data from individual hamsters. Bar color indicates vaccine group (VLP-614D-S/VLP-SHC014-S: green pattern; VLP-614D-S/VLP-SHC014-S/VLP-BA.2.75.2-S: red pattern; VLP-614D-S/VLP-SHC014-S/VLP-XBB-S: cyan pattern; VLP control or PBS: white). a FRNT50 neutralization titers against indicated viruses after immunization with VLP-S mixtures or Pfizer-BioNTech Bivalent mRNA vaccine. (geometric mean with geometric SD, n = 3: sera from 3 hamsters for VLP-S; n = 4: sera from 4 hamsters for Pfizer-BioNTech vaccine). † - No neutralization titers detected. ND – Not determined. Detection limit (dotted line) = 20. b Viral titers in the lungs of hamsters immunized with VLP-S cocktails or VLP-control three days after infection with BA.5 or XBB.1 (mean with SD, n = 3: tissue from 3 hamsters for VLP-S and XBB.1 VLP-control; n = 6: tissue from 6 hamsters for BA.5 VLP-control). ****P < 0.0001, determined by a Brown-Forsythe and Welch ANOVA test and Dunnett’s T3 multiple comparisons between groups. For Fig. 4b–e, † - No infectious virus was detected; detection limit (dotted line) = 1.3 log10 pfu/g. c Viral titers in the lungs of hamsters immunized with Pfizer-BioNTech Bivalent mRNA vaccine or PBS three days after infection with XBB.1 (mean with SD, n = 4: tissue from 4 hamsters). **P = 0.0031, determined by two-tailed unpaired Student’s t test. d Viral titers in the nasal turbinates of hamsters immunized with VLP-S cocktails or VLP-control three days after infection with BA.5 or XBB.1 (mean with SD, n = 3: tissue from 3 hamsters for VLP-S and XBB.1 VLP-control; n = 6: tissue from 6 hamsters for BA.5 VLP-control). *P = 0.0396, **P < 0.01 (VLP-control vs VLP-614D-S/VLP-SHC014-S: P = 0.0040; VLP-control vs VLP-614D-S/VLP-SHC014-S/VLP-XBB-S: P = 0.0010; VLP-control vs VLP-614D-S/VLP-SHC014-S/VLP-BA.2.75.2-S: P = 0.0010), ***P = 0.0008, determined by a Brown-Forsythe and Welch ANOVA test and Dunnett’s T3 multiple comparisons between groups. e Viral titers in the nasal turbinates of hamsters immunized with Pfizer-BioNTech Bivalent mRNA vaccine or PBS three days after infection with XBB.1 (mean with SD, n = 4: tissue from 4 hamsters). **P = 0.0021, determined by two-tailed unpaired Student’s t test.

Back to article page